Table 1.

Baseline patient characteristics

	Transfem GA (n=51)	Transfem LASedation (n=66)	Transapical (n=59)
Age (years)	86 (82-88)	86 (83-88)	84 (81-87)
BMI (kg/m2)	25 (22-29)	26 (22-27)	27 (23-31)
Male sex (%)	31 (61)	26 (39)	34 (58)
Creatinine (mg/dL)	1.24 (1.03-1.55)	1.14 (0.89-1.53)	1.29 (1.02-1.85)
GFR (ml/min)	51 (41-67)	55 (41-66)	42 (30-65)
BNP (ng/L)	396 (216-539)	430 (169-1277)	310 (197-623)
Hb (g/dL)	12.6 (11.1-13.8)	12.7 (10.8-13.4)	12.1 (10.5-13.0)
EuroSCORE II (%)	5.5 (3.7-10.6)	4.9 (2.7-8.5)	8.6 (4.6-13.3)*
Logistic EuroSCORE (%)	25.28 (16.30-38.90)	27.14 (14.55-39.96)	31.80 (21.32-46.75)
FS (%)	29 (20-36)	27 (18-40)	33 (24-42)
PG aortic valve (mmHg)	74 (52-86)	70 (55-94)	78 (55-87)
Aortic surface (cm2)	0.6 (0.5-0.7)	0.6 (0.5-0.7)	0.6 (0.5-0.7)
Ischemic cardiomyopathy (%)	39 (76)	40 (61)	47 (80)
History of CVA or TIA (%)	12 (24)	12 (18)	11 (19)
History of arrhythmias (%)	24 (47)	23 (35)	24 (41)
Diabetes (%)	15 (29)	13 (20)	7 (12)
COPD (%)	12 (24)	25 (38)	16 (27)
Redo surgery (%)	13 (25)	11 (17)	25 (42)**
Pulmonary hypertension (%)	10 (20)	9 (14)	9 (15)
NYHA II (%)	17 (33)	23 (35)	19 (32)
NYHA III (%)	32 (63)	35 (53)	36 (61)
NYHA IV (%)	2 (4)	8 (12)	4 (7)

All data are expressed in median (percentile 25-75) or numbers (%). *P<0.05: Compared with other two groups, **P<0.05: Transapical versus Transfem LASedation. Transfem GA: Transfemoral general anesthesia, Transfem LASedation: Transfemoral local anesthesia±sedation, BMI: Body mass index, GFR: Glomerular filtration rate, BNP: Brain natriuretic peptide, Hb: Hemoglobin, EuroSCORE II: European System for Cardiac Operative Risk Evaluation II, FS: Fractional shortening, PG: Peak gradient, CVA: Cerebrovascular accident, TIA: Transient ischemic attack, COPD: Chronic obstructive pulmonary disease, NYHA: New York Heart Association